Biogen seeks to retain lead in MS market with US BG-12 submission
This article was originally published in Scrip
Executive Summary
Biogen Idec is aiming to preserve its leadership role in the multiple sclerosis (MS) space by bringing its oral therapeutic candidate BG-12 (dimethyl fumarate) to the US market before the end of the year.